Difference between revisions of "Part:BBa K5189006"
(3 intermediate revisions by 2 users not shown) | |||
Line 3: | Line 3: | ||
<partinfo>BBa_K5189006 short</partinfo> | <partinfo>BBa_K5189006 short</partinfo> | ||
− | |||
− | |||
− | |||
− | |||
− | |||
<!-- --> | <!-- --> | ||
Line 13: | Line 8: | ||
<partinfo>BBa_K5189006 SequenceAndFeatures</partinfo> | <partinfo>BBa_K5189006 SequenceAndFeatures</partinfo> | ||
+ | <html lang="en"> | ||
+ | <head> | ||
+ | <meta charset="UTF-8"> | ||
+ | <meta name="viewport" content="width=device-width, initial-scale=1.0"> | ||
+ | <title>BBa_K5189006 (pRSFduet-metF-folA) Documentation</title> | ||
+ | </head> | ||
+ | <body> | ||
− | <!-- | + | <!-- Composite Part Overview Section --> |
− | ===Functional | + | <h2>Composite Part: BBa_K5189006 (pRSFduet-metF-folA)</h2> |
− | < | + | |
− | <!-- --> | + | <!-- Construction Design Section --> |
+ | <h3>Construction Design</h3> | ||
+ | <p>The pRSFduet-metF-folA plasmid was constructed by selecting and amplifying the <em>metF</em> and <em>folA</em> genes to optimize the L-5-MTHF production pathway. The pRSFduet-1 vector was chosen due to its capability to accommodate multiple gene insertions and its strong, regulated expression under the T7 promoter. The <em>metF</em> gene (894 bp) and <em>folA</em> gene (480 bp) were amplified via PCR and inserted into the pRSFduet-1 vector.</p> | ||
+ | |||
+ | <!-- Figure 1 --> | ||
+ | <div style="text-align:center;"> | ||
+ | <img src="https://static.igem.wiki/teams/5189/bba-k5189006/1.png" width="50%" alt="Figure 1: The plasmid map of pRSFduet-metF-folA"> | ||
+ | <div style="text-align:center;"> | ||
+ | <caption>Figure 1: The plasmid map of pRSFduet-metF-folA</caption> | ||
+ | </div> | ||
+ | </div> | ||
+ | |||
+ | <!-- Cultivation and Purification Section --> | ||
+ | <h3>Cultivation, Purification, and SDS-PAGE</h3> | ||
+ | <p>The <em>metF</em> and <em>folA</em> genes were successfully amplified using PCR, yielding bands of 894 bp and 480 bp, respectively. The <em>metF</em> gene was inserted into the pRSFduet-1 vector by digestion with BamHI and HindIII, while the <em>folA</em> gene was inserted using NdeI and XhoI. The recombinant plasmid was then transformed into <em>E. coli</em> DH5α. Validation was performed using colony PCR and enzyme digestion, with gel electrophoresis confirming successful ligation.</p> | ||
+ | |||
+ | <!-- Figure 2 --> | ||
+ | <div style="text-align:center;"> | ||
+ | <img src="https://static.igem.wiki/teams/5189/bba-k5189006/2.png" width="40%" alt="Figure 2: Gel electrophoresis validation of metF and folA nucleic acids"> | ||
+ | <div style="text-align:center;"> | ||
+ | <caption>Figure 2: The gel electrophoresis validation of metF (Left) and folA (Right) nucleic acids</caption> | ||
+ | </div> | ||
+ | </div> | ||
+ | |||
+ | <p>Upon verifying the successful amplification of the targeted plasmid, they were transformed into <em>E. coli</em> DH5α. Selected colonies were sequenced for verification.</p> | ||
+ | |||
+ | <!-- Figure 3 --> | ||
+ | <div style="text-align:center;"> | ||
+ | <img src="https://static.igem.wiki/teams/5189/bba-k5189006/3.png" width="30%" alt="Figure 3: Transformation plate and enzyme digestion verification for pRSF-metF-folA"> | ||
+ | <div style="text-align:center;"> | ||
+ | <caption>Figure 3: Transformation plate of pRSFDuet-metF-folA (A); Enzyme digestion verification (B), (C); Sequencing results (D)</caption> | ||
+ | </div> | ||
+ | </div> | ||
+ | |||
+ | <!-- Characterization and Measurement Section --> | ||
+ | <h3>Characterization and Measurement</h3> | ||
+ | <p>The pRSFDuet-metF-folA plasmid was transformed into <em>E. coli</em> BL21(DE3) to evaluate the co-expression of the <em>metF</em> and <em>folA</em> genes. Protein expression was induced using IPTG and analyzed via SDS-PAGE and Western Blot techniques. The SDS-PAGE results displayed distinct bands corresponding to the <em>metF</em> and <em>folA</em> proteins, particularly under induction at 37°C. Western Blot analysis confirmed the successful expression of all proteins, demonstrating effective co-expression.</p> | ||
+ | |||
+ | <!-- Figure 4 --> | ||
+ | <div style="text-align:center;"> | ||
+ | <img src="https://static.igem.wiki/teams/5189/bba-k5189006/4.png" width="50%" alt="Figure 4: SDS-PAGE and Western Blot analysis of metF and folA proteins"> | ||
+ | <div style="text-align:center;"> | ||
+ | <caption>Figure 4: Expression of metF and folA Proteins in BL21(DE3) Analyzed by SDS-PAGE (left) and Western Blot (right)</caption> | ||
+ | </div> | ||
+ | </div> | ||
+ | |||
+ | <p>To further investigate the production pathway of L-5-MTHF, we co-transformed the constructed pETduet-ftfL-fchA-mtdA recombinant plasmid with the pRSFduet-metF-folA recombinant plasmid into <em>E. coli</em> BL21 (DE3). Colony PCR verified that strain A was constructed successfully.</p> | ||
+ | |||
+ | <!-- Figure 5 --> | ||
+ | <div style="text-align:center;"> | ||
+ | <img src="https://static.igem.wiki/teams/5189/bba-k5189006/5.jpg" width="50%" alt="Figure 5: Colony PCR validation for co-transformed strains"> | ||
+ | <div style="text-align:center;"> | ||
+ | <caption>Figure 5: Construction of co-transformed strains; A: Colony PCR validation for pRSFduet-metF-folA; B: Colony PCR validation for pETduet-ftfL-mtdA-fchA; C: Colony A plate diagram</caption> | ||
+ | </div> | ||
+ | </div> | ||
+ | |||
+ | <!-- Functional Test Section --> | ||
+ | <h3>Functional Test</h3> | ||
+ | |||
+ | <!-- 1. One-Step Growth Curve Analysis --> | ||
+ | <h4>1. One-Step Growth Curve Analysis</h4> | ||
+ | <p>A one-step growth curve was generated to compare the growth rates of different strains. The control strain, BL21, exhibited rapid growth, transitioning into the stationary phase after about 10 hours. In contrast, strains pRSF-metF-folA, pET-ftfL-mtdA-fchA, and Strain A (containing both the pRSFDuet-metF-folA and pETduet-ftfL-mtdA-fchA plasmids) showed slower initial growth rates but continued growing past the 12-hour mark. This suggests that Strain A may have a higher potential for sustained growth due to the combined effects of both plasmids enhancing L-5-MTHF production.</p> | ||
+ | |||
+ | <!-- Figure 6 --> | ||
+ | <div style="text-align:center;"> | ||
+ | <img src="https://static.igem.wiki/teams/5189/bba-k5189006/6.png" width="40%" alt="Figure 6: One-step growth curve analysis for BL21 and co-transformed strains"> | ||
+ | <div style="text-align:center;"> | ||
+ | <caption>Figure 6: One-Step Growth Curve for BL21, pRSF-metF-folA, pET-ftfL-mtdA-fchA, and Strain A</caption> | ||
+ | </div> | ||
+ | </div> | ||
+ | |||
+ | <!-- 2. HPLC Assay for L-5-MTHF Yield --> | ||
+ | <h4>2. HPLC Assay for L-5-MTHF Yield</h4> | ||
+ | <p>To determine the actual yield of L-5-MTHF, we utilized HPLC. The constructed host bacteria were inoculated into LB medium supplemented with folic acid and sodium formate, and incubated at 37°C. After inducing protein expression with IPTG, L-5-MTHF concentrations were measured at different time intervals using HPLC.</p> | ||
+ | |||
+ | <p>The measured results show that strain A, after co-transformation, produced higher L-5-MTHF compared to the control BL21 strain. The data indicated that the addition of folic acid and the expression of the enzyme in Strain A led to a higher yield of biologically active L-5-MTHF.</p> | ||
+ | |||
+ | <!-- Table 1: L-5-MTHF concentration --> | ||
+ | <h4>Table 1. L-5-MTHF concentration of BL21 and Strains A</h4> | ||
+ | <table border="1" cellpadding="5" cellspacing="0" style="width: 70%; text-align: center;"> | ||
+ | <thead> | ||
+ | <tr> | ||
+ | <th>Time</th> | ||
+ | <th>L-5-MTHF concentration of BL21 (16℃)</th> | ||
+ | <th>L-5-MTHF concentration of BL21 (37℃)</th> | ||
+ | <th>L-5-MTHF concentration of Strains A (16℃)</th> | ||
+ | <th>L-5-MTHF concentration of Strains A (37℃)</th> | ||
+ | </tr> | ||
+ | </thead> | ||
+ | <tbody> | ||
+ | <tr> | ||
+ | <td>0h</td> | ||
+ | <td>0.308</td> | ||
+ | <td>0.268</td> | ||
+ | <td>0.451</td> | ||
+ | <td>0.400</td> | ||
+ | </tr> | ||
+ | <tr> | ||
+ | <td>2h</td> | ||
+ | <td>0.322</td> | ||
+ | <td>0.222</td> | ||
+ | <td>0.605</td> | ||
+ | <td>0.488</td> | ||
+ | </tr> | ||
+ | <tr> | ||
+ | <td>4h</td> | ||
+ | <td>0.315</td> | ||
+ | <td>0.250</td> | ||
+ | <td>0.697</td> | ||
+ | <td>0.550</td> | ||
+ | </tr> | ||
+ | <tr> | ||
+ | <td>10h</td> | ||
+ | <td>0.328</td> | ||
+ | <td>0.234</td> | ||
+ | <td>0.719</td> | ||
+ | <td>0.608</td> | ||
+ | </tr> | ||
+ | <tr> | ||
+ | <td>22h</td> | ||
+ | <td>0.375</td> | ||
+ | <td>0.276</td> | ||
+ | <td>0.836</td> | ||
+ | <td>0.714</td> | ||
+ | </tr> | ||
+ | <tr> | ||
+ | <td>32h</td> | ||
+ | <td>0.304</td> | ||
+ | <td>0.228</td> | ||
+ | <td>0.946</td> | ||
+ | <td>0.821</td> | ||
+ | </tr> | ||
+ | <tr> | ||
+ | <td>48h</td> | ||
+ | <td>0.331</td> | ||
+ | <td>0.256</td> | ||
+ | <td>1.498</td> | ||
+ | <td>0.926</td> | ||
+ | </tr> | ||
+ | </tbody> | ||
+ | </table> | ||
+ | |||
+ | <p>The table shows that L-5-MTHF concentration in Strain A was significantly higher than the control BL21 strain at all time points, indicating that the co-expression of the plasmids enhanced L-5-MTHF production.</p> | ||
+ | |||
+ | <!-- Figure 7 --> | ||
+ | <div style="text-align:center;"> | ||
+ | <img src="https://static.igem.wiki/teams/5189/bba-k5189006/7.jpg" width="50%" alt="Figure 7: L-5-MTHF production over time"> | ||
+ | <div style="text-align:center;"> | ||
+ | <caption>Figure 7: Variation of L-5-MTHF production over time</caption> | ||
+ | </div> | ||
+ | </div> | ||
+ | |||
+ | <p>The data in Figure 7 shows that the control strain BL21 did not experience significant fluctuations in L-5-MTHF production over time. In contrast, Strain A saw a gradual increase in L-5-MTHF production, reaching its maximum value at 48 hours. Due to oxidation and sample depletion during the experimental process, the actual production of active L-5-MTHF may have been slightly higher than the measured values.</p> | ||
+ | |||
+ | <!-- Summary Section --> | ||
+ | <h3>Summary</h3> | ||
+ | <p>In conclusion, we successfully increased the production of L-5-MTHF by genetically engineering the metabolic pathway of <em>E. coli</em> BL21. The co-expression of the <em>metF</em>, <em>folA</em>, <em>ftfL</em>, <em>mtdA</em>, and <em>fchA</em> genes enhanced the yield of biologically active L-5-MTHF. Notably, the product of methionine synthase MTRR (encoded by the <em>metH</em> gene) in the metabolic pathway inhibits the activity of MTHFR in the L-5-MTHF synthesis pathway, further affecting the yield of L-5-MTHF. Future studies will explore the impact of knocking down the <em>metH</em> gene on the entire metabolic pathway and the strain's growth characteristics.</p> | ||
+ | |||
+ | <!-- References Section --> | ||
+ | <h3>References</h3> | ||
+ | <ol> | ||
+ | <li>Ismail S, Eljazzar S, Ganji V. 2023. Intended and Unintended Benefits of Folic Acid Fortification—A Narrative Review. Foods 12:1612.</li> | ||
+ | </ol> | ||
+ | |||
+ | </body> | ||
+ | </html> |
Latest revision as of 05:51, 29 September 2024
pRSFduet-metF-folA
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12INCOMPATIBLE WITH RFC[12]Illegal NotI site found at 137
- 21INCOMPATIBLE WITH RFC[21]Illegal BglII site found at 293
Illegal BamHI site found at 106
Illegal XhoI site found at 342 - 23COMPATIBLE WITH RFC[23]
- 25INCOMPATIBLE WITH RFC[25]Illegal NgoMIV site found at 312
Illegal AgeI site found at 554 - 1000INCOMPATIBLE WITH RFC[1000]Illegal BsaI site found at 627
Composite Part: BBa_K5189006 (pRSFduet-metF-folA)
Construction Design
The pRSFduet-metF-folA plasmid was constructed by selecting and amplifying the metF and folA genes to optimize the L-5-MTHF production pathway. The pRSFduet-1 vector was chosen due to its capability to accommodate multiple gene insertions and its strong, regulated expression under the T7 promoter. The metF gene (894 bp) and folA gene (480 bp) were amplified via PCR and inserted into the pRSFduet-1 vector.
Cultivation, Purification, and SDS-PAGE
The metF and folA genes were successfully amplified using PCR, yielding bands of 894 bp and 480 bp, respectively. The metF gene was inserted into the pRSFduet-1 vector by digestion with BamHI and HindIII, while the folA gene was inserted using NdeI and XhoI. The recombinant plasmid was then transformed into E. coli DH5α. Validation was performed using colony PCR and enzyme digestion, with gel electrophoresis confirming successful ligation.
Upon verifying the successful amplification of the targeted plasmid, they were transformed into E. coli DH5α. Selected colonies were sequenced for verification.
Characterization and Measurement
The pRSFDuet-metF-folA plasmid was transformed into E. coli BL21(DE3) to evaluate the co-expression of the metF and folA genes. Protein expression was induced using IPTG and analyzed via SDS-PAGE and Western Blot techniques. The SDS-PAGE results displayed distinct bands corresponding to the metF and folA proteins, particularly under induction at 37°C. Western Blot analysis confirmed the successful expression of all proteins, demonstrating effective co-expression.
To further investigate the production pathway of L-5-MTHF, we co-transformed the constructed pETduet-ftfL-fchA-mtdA recombinant plasmid with the pRSFduet-metF-folA recombinant plasmid into E. coli BL21 (DE3). Colony PCR verified that strain A was constructed successfully.
Functional Test
1. One-Step Growth Curve Analysis
A one-step growth curve was generated to compare the growth rates of different strains. The control strain, BL21, exhibited rapid growth, transitioning into the stationary phase after about 10 hours. In contrast, strains pRSF-metF-folA, pET-ftfL-mtdA-fchA, and Strain A (containing both the pRSFDuet-metF-folA and pETduet-ftfL-mtdA-fchA plasmids) showed slower initial growth rates but continued growing past the 12-hour mark. This suggests that Strain A may have a higher potential for sustained growth due to the combined effects of both plasmids enhancing L-5-MTHF production.
2. HPLC Assay for L-5-MTHF Yield
To determine the actual yield of L-5-MTHF, we utilized HPLC. The constructed host bacteria were inoculated into LB medium supplemented with folic acid and sodium formate, and incubated at 37°C. After inducing protein expression with IPTG, L-5-MTHF concentrations were measured at different time intervals using HPLC.
The measured results show that strain A, after co-transformation, produced higher L-5-MTHF compared to the control BL21 strain. The data indicated that the addition of folic acid and the expression of the enzyme in Strain A led to a higher yield of biologically active L-5-MTHF.
Table 1. L-5-MTHF concentration of BL21 and Strains A
Time | L-5-MTHF concentration of BL21 (16℃) | L-5-MTHF concentration of BL21 (37℃) | L-5-MTHF concentration of Strains A (16℃) | L-5-MTHF concentration of Strains A (37℃) |
---|---|---|---|---|
0h | 0.308 | 0.268 | 0.451 | 0.400 |
2h | 0.322 | 0.222 | 0.605 | 0.488 |
4h | 0.315 | 0.250 | 0.697 | 0.550 |
10h | 0.328 | 0.234 | 0.719 | 0.608 |
22h | 0.375 | 0.276 | 0.836 | 0.714 |
32h | 0.304 | 0.228 | 0.946 | 0.821 |
48h | 0.331 | 0.256 | 1.498 | 0.926 |
The table shows that L-5-MTHF concentration in Strain A was significantly higher than the control BL21 strain at all time points, indicating that the co-expression of the plasmids enhanced L-5-MTHF production.
The data in Figure 7 shows that the control strain BL21 did not experience significant fluctuations in L-5-MTHF production over time. In contrast, Strain A saw a gradual increase in L-5-MTHF production, reaching its maximum value at 48 hours. Due to oxidation and sample depletion during the experimental process, the actual production of active L-5-MTHF may have been slightly higher than the measured values.
Summary
In conclusion, we successfully increased the production of L-5-MTHF by genetically engineering the metabolic pathway of E. coli BL21. The co-expression of the metF, folA, ftfL, mtdA, and fchA genes enhanced the yield of biologically active L-5-MTHF. Notably, the product of methionine synthase MTRR (encoded by the metH gene) in the metabolic pathway inhibits the activity of MTHFR in the L-5-MTHF synthesis pathway, further affecting the yield of L-5-MTHF. Future studies will explore the impact of knocking down the metH gene on the entire metabolic pathway and the strain's growth characteristics.
References
- Ismail S, Eljazzar S, Ganji V. 2023. Intended and Unintended Benefits of Folic Acid Fortification—A Narrative Review. Foods 12:1612.